# Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

> **NCT00310817** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 623 (actual)

## Conditions studied

- Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** MenACWY-CRM conjugate vaccine, adjuvanted
- **BIOLOGICAL:** MenACWY polysaccharide vaccine
- **BIOLOGICAL:** MenACWY-CRM conjugate vaccine, unadjuvanted

## Key facts

- **NCT ID:** NCT00310817
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 623 (ACTUAL)
- **Last updated:** 2015-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310817, "Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00310817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*